Search

Your search keyword '"Kakuta, Yoichi"' showing total 882 results
Start Over Author "Kakuta, Yoichi"
882 results on '"Kakuta, Yoichi"'

101. Tu1453: EFFICACY OF RISANKIZUMAB RESCUE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE AND INADEQUATE RESPONSE TO RISANKIZUMAB MAINTENANCE THERAPY

Author

Baert, Filip J., primary, Atreya, Raja, additional, Kakuta, Yoichi, additional, Long, Millie D., additional, Roblin, Xavier, additional, Neimark, Ezequiel, additional, Song, Alexandra P., additional, Wallace, Kori, additional, Kligys, Kristina, additional, Mallick, Madhuja, additional, Liao, Xiaomei, additional, and Lim, Allen, additional

Published
2022
Full Text
View/download PDF

104. Effectiveness of colonic stent placement for obstructive colorectal cancers: An analysis of short‐term results using a nationwide database in Japan

Author

Moroi, Rintaro, primary, Tarasawa, Kunio, additional, Shimoyama, Yusuke, additional, Kuroha, Masatake, additional, Shiga, Hisashi, additional, Kakuta, Yoichi, additional, Fushimi, Kiyohide, additional, Fujimori, Kenji, additional, Kinouchi, Yoshitaka, additional, and Masamune, Atsushi, additional

Published
2022
Full Text
View/download PDF

106. TL1A (TNFSF15) genotype affects the long‐term therapeutic outcomes of anti‐TNFα antibodies for Crohn's disease patients

Author

Endo, Katsuya, Kakuta, Yoichi, Moroi, Rintaro, Yamamoto, Katsutoshi, Shiga, Hisashi, Kuroha, Masatake, Naito, Takeo, Kinouchi, Yoshitaka, and Masamune, Atsushi

Subjects
Crohn's disease, TL1A (TNFSF15), adalimumab, Original Article, Original Articles, infliximab
Abstract

Background and Aim TL1A (TNFSF15) is a major Crohn's disease (CD) susceptibility gene, especially in the East Asian population, and is also known to be associated with some clinical phenotypes, such as stricturing and penetrating behavior. This study aims to investigate the association between TL1A genotype and the long‐term therapeutic outcomes of infliximab and adalimumab in Japanese CD patients. Methods We investigated 119 biologic‐naïve CD patients treated with infliximab or adalimumab. TL1A ‐358C/T (rs6478109) was genotyped as a tag single nucleotide polymorphism (SNP) for CD risk or nonrisk haplotype of TL1A (the ‐358C allele is a risk allele for CD development). We compared the long‐term therapeutic outcomes of anti‐tumor necrosis factor (TNF) antibodies between the TL1A ‐358C/C group and the C/T+T/T group. Results Sixty‐nine cases (58.0%) were homozygous for the risk allele (TL1A ‐358C/C group), and 50 cases (42.0%) were heterozygous for the risk allele or homozygous for the protective allele (TL1A ‐358C/T+T/T group). No significant differences were found in the cumulative retention rates and the relapse‐free survival between the TL1A genotypes. However, the surgery‐free survival was significantly lower in the TL1A ‐358C/C group than in the C/T+T/T group (log‐rank test, P, In this study, we investigated the association between TL1A genotype and the long‐term therapeutic outcomes of infliximab and adalimumab in Crohn's disease (CD) patients. We investigated 119 biologic‐naïve CD patients treated with infliximab or adalimumab and found an association between the TL1A genotype and surgery‐free survival during anti‐tumor necrosis factor (TNF) therapy. The patients whose genotypes are homozygous for the TL1A ‐358C (risk allele of CD development) show lower surgery‐free survival with anti‐TNF treatment.

Published
2020

112. A study of the mechanisms responsible for the action of new immunosuppressants and their effects on rat small intestinal transplantation

Author

Miyagawa, Shuji, primary, Kodama, Tasuku, additional, Matsuura, Rei, additional, Lo, Pei-Chi, additional, Sakai, Rieko, additional, Toyama, Chiyoshi, additional, Takama, Yuichi, additional, Ihara, Yoshiyuki, additional, Kakuta, Yoichi, additional, Yamanaka, Kazuaki, additional, Matsunami, Katsuyoshi, additional, Eguchi, Hiroshi, additional, Maeda, Akira, additional, and Okuyama, Hiroomi, additional

Published
2022
Full Text
View/download PDF

113. Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with NUDT15 heterozygosity

Author

Maeda, Takato, primary, Sakuraba, Hirotake, additional, Hiraga, Hiroto, additional, Yoshida, Shukuko, additional, Kakuta, Yoichi, additional, Kikuchi, Hidezumi, additional, Kawaguchi, Shogo, additional, Hasui, Keisuke, additional, Tatsuta, Tetsuya, additional, Chinda, Daisuke, additional, Mikami, Tatsuya, additional, and Fukuda, Shinsaku, additional

Published
2022
Full Text
View/download PDF

114. Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study

Author

Imamura, Ryoichi, primary, Tanaka, Ryo, additional, Taniguchi, Ayumu, additional, Nakazawa, Shigeaki, additional, Kato, Taigo, additional, Yamanaka, Kazuaki, additional, Namba-Hamano, Tomoko, additional, Kakuta, Yoichi, additional, Abe, Toyofumi, additional, Tsutahara, Koichi, additional, Takao, Tetsuya, additional, Kishikawa, Hidefumi, additional, and Nonomura, Norio, additional

Published
2022
Full Text
View/download PDF

115. The Impact of Concomitant Ulcerative Colitis on the Clinical Course in Patients with Primary Sclerosing Cholangitis: An Investigation Using a Nationwide Database in Japan

Author

Moroi, Rintaro, primary, Yano, Kota, additional, Tarasawa, Kunio, additional, Shimoyama, Yusuke, additional, Naito, Takeo, additional, Shiga, Hisashi, additional, Hamada, Shin, additional, Kakuta, Yoichi, additional, Fushimi, Kiyohide, additional, Fujimori, Kenji, additional, Kinouchi, Yoshitaka, additional, and Masamune, Atsushi, additional

Published
2022
Full Text
View/download PDF

116. Analysis of the disease activity of ulcerative colitis with and without concomitant primary sclerosing cholangitis: An investigation using a nationwide database in Japan

Author

Yano, Kota, primary, Moroi, Rintaro, additional, Shiga, Hisashi, additional, Tarasawa, Kunio, additional, Shimoyama, Yusuke, additional, Kuroha, Masatake, additional, Hamada, Shin, additional, Kakuta, Yoichi, additional, Fushimi, Kiyohide, additional, Fujimori, Kenji, additional, Kinouchi, Yoshitaka, additional, and Masamune, Atsushi, additional

Published
2021
Full Text
View/download PDF

119. Current Status and Future Prospects of Inflammatory Bowel Disease Genetics.

Author

Kakuta, Yoichi, Naito, Takeo, Kinouchi, Yoshitaka, and Masamune, Atsushi

Subjects
*INFLAMMATORY bowel diseases, *GENETICS, *GENOME-wide association studies, *GENETIC techniques
Abstract

Background: The genetic background of inflammatory bowel diseases (IBDs) has been explored using genetic analysis techniques, such as genome-wide association studies for the population and whole-exome sequencing analyses of family lineages in cases of very early onset. Summary: The results of genetic analysis for IBD indicated the involvement of innate and adaptive immune system variations and epithelial abnormalities in the pathogenesis of IBD. Several associated genes were also reported, indicating that IBD occurs in a heterogeneous population with an extremely diverse background. The genetic background of IBDs is currently being studied to understand not only its onset but also its prognosis, response to treatment, and adverse effects. In the future, it will be possible to use an individual's genetic information for determining appropriate treatment. In Japan, the NUDT15 polymorphism test is performed before administering thiopurine preparations. However, because of racial differences in genetic analysis, biased analysis toward some racial groups may result in overlooking important genetic backgrounds of IBD. Key Message: Studies of IBDs in a more diverse range of races are expected to elucidate genetic factors through a transethnic analysis, thereby aiding the development of novel treatments and precision medicine for IBDs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

120. Response to COVID‐19 vaccine is reduced in patients with inflammatory bowel disease, but improved with additional dose.

Author

Shiga, Hisashi, Kakuta, Yoichi, An, Kumiko, Abe, Yuko, Fujimaki, Shinichi, Shimoyama, Yusuke, Naito, Takeo, Moroi, Rintaro, Kuroha, Masatake, Khor, Seik‐Soon, Kawai, Yosuke, Tokunaga, Katsushi, Kinouchi, Yoshitaka, and Masamune, Atsushi

Subjects
*INFLAMMATORY bowel diseases, *CROHN'S disease, *VACCINE effectiveness, *COVID-19 vaccines, *COVID-19
Abstract

Background: Coronavirus disease 2019 (COVID‐19) vaccination is recommended for patients with inflammatory bowel disease (IBD); however, suppressed immune responses have been reported for fully vaccinated patients under immunosuppressive therapy, mainly from Western countries. We prospectively analyzed antibody titers of IBD patients in Asia induced by two‐dose and additional dose of messengerRNA COVID‐19 vaccine. Methods: After measuring high‐affinity antibody titers, factors associated with antibody titers were identified by multiple regression analyses using the following covariates: sex, age (≥60 or <60 years), disease type (Crohn's disease or ulcerative colitis), vaccine type (BNT162b2 or mRNA‐1273), time from second/third vaccination, molecular‐targeted agent (anti‐tumor necrosis factor [TNF] agents, ustekinumab, vedolizumab, tofacitinib, or no molecular‐targeted agents), thiopurine, steroid, and 5‐aminosalicylic acid. Results: Among 409 patients analyzed, mean titer was 1316.7 U/mL (SD, 1799.3); 403 (98.5%) were judged to be seropositive (≥0.8 U/mL), and 389 (95.1%) had neutralizing antibodies (≥15 U/mL). After the third vaccination, mean titer raised up to 21 123.8 U/mL (SD, 23 474.5); all 179 were seropositive, and 178 (99.4%) had neutralizing antibodies. In 248 patients with genetic data, there was no difference in mean titer after two/third doses between carriers and non‐carriers of HLA‐A24 associated with severe disease during COVID‐19 infection. A multiple regression analyses using covariates revealed that older age, vaccine type (BNT162b2), time from second/third dose, anti‐TNF agent, tofacitinib, and thiopurine were independently associated with lower antibody titers. Conclusions: Our findings further support the recommendation for COVID‐19 vaccination in patients under immunosuppressive therapy, especially additional third dose for patients receiving anti‐TNF agents and/or thiopurine or tofacitinib. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

121. Severity of acute pancreatitis in patients with inflammatory bowel disease in the era of biologics: A propensity‐score‐matched analysis using a nationwide database in Japan.

Author

Moroi, Rintaro, Tarasawa, Kunio, Ikeda, Mio, Matsumoto, Ryotaro, Shimoyama, Yusuke, Naito, Takeo, Takikawa, Tetsuya, Shiga, Hisashi, Hamada, Shin, Kakuta, Yoichi, Kikuta, Kazuhiro, Fushimi, Kiyohide, Fujimori, Kenji, Kinouchi, Yoshitaka, and Masamune, Atsushi

Subjects
INFLAMMATORY bowel diseases, CROHN'S disease, INTESTINAL diseases, PANCREATITIS, ULCERATIVE colitis, BIOLOGICALS
Abstract

Background and Aim: Acute pancreatitis (AP) is a rare extraintestinal manifestation of inflammatory bowel disease (IBD). Several studies from Western countries have reported that the severity of AP in patients with IBD is similar to that in the general population; however, its severity in patients from Eastern countries in the era of biologics remains unclear. This study aimed to investigate the severity of AP in patients with IBD and the effect of biologics on the severity of AP using a nationwide database. Methods: We divided 1138 eligible AP admissions from the Diagnosis Procedure Combination database system into IBD and non‐IBD groups after propensity score matching, and compared the severity of AP. We divided the IBD group into ulcerative colitis (UC) and Crohn's disease (CD) subgroups and compared each with the non‐IBD group. Logistic regression analysis was conducted to identify the clinical factors affecting acute pancreatitis. Results: IBD and UC groups had lower rate of severe AP compared to the non‐IBD group (13.7% vs 28.3%, P < 0.0001 and 11.0% vs 28.3%, P < 0.0001, respectively). There were no differences in the rates of severe AP between the CD and non‐IBD groups. Multivariate analysis showed that biologics did not affect the severity of AP. Conclusion: The severity of AP in patients with IBD may be lower than that in the general population; biologics for IBD may not worsen its severity. Further prospective studies are required to clarify the severity of AP in patients with IBD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

124. Colonic Stent Placement May Reduce Mortality Rate and Length of Hospitalization in Obstructive Colorectal Cancer Cases: a Propensity Score-matched Analysis Using a Nationwide Database in Japan

Author

Moroi, Rintaro, primary, Tarasawa, Kunio, additional, Shimoyama, Yusuke, additional, Kuroha, Masatake, additional, Shiga, Hisashi, additional, Kakuta, Yoichi, additional, Fushimi, Kiyohide, additional, Fujimori, Kenji, additional, Kinouchi, Yoshitaka, additional, and Masamune, Atsushi, additional

Published
2021
Full Text
View/download PDF

125. Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation between Prognosis and Disease Susceptibility Loci

Author

Hishinuma, Kasumi, primary, Moroi, Rintaro, additional, Okamoto, Daisuke, additional, Shimoyama, Yusuke, additional, Kuroha, Masatake, additional, Shiga, Hisashi, additional, Kakuta, Yoichi, additional, Kinouchi, Yoshitaka, additional, and Masamune, Atsushi, additional

Published
2021
Full Text
View/download PDF

126. A Case of Perivascular Epithelioid Cell Tumor (PEComa) of the Uterus Associated with Tuberous Sclerosis Complex Diagnosed by Intra-Abdominal Bleeding from the Uterus

Author

Taniguchi, Ayumu, Kakuta, Yoichi, Fujita, Kazutoshi, Uemura, Motohide, Kiuchi, Hiroshi, Imamura, Ryoichi, Miyagawa, Yasushi, Nonomura, Norio, and Ueda, Yutaka

Subjects
Perivascular epithelioid cell tumor, Tuberous sclerosis, Uterus, 494.9
Abstract

We report a case of perivascular epithelioid cell tumor (PEComa) of the uterus associated with tuberous sclerosis complex discovered as a result of intraabdominal bleeding. A 54-year-old woman visited the department of obstetrics and gynecology with chief complaints of genital bleeding and abdominal pain lasting three weeks. Abdominal computed tomography (CT) revealed intraabdominal bleeding from the uterine corpus. She had a history of bilateral renal angiomyolipoma, which was treated with partial bilateral nephrectomy at age 25. Moreover, pulmonary lymphangioleiomyomatosis was diagnosed at age 43. Both conditions were detected by the CT scan during this hospitalization. Immediately after the CT scans, the patient entered a state of hemorrhagic shock, and we performed an emergency simple total hysterectomy. Histopathological examination on the resected specimen yielded a diagnosis of uterine perivascular epithelial cell tumor (PEComa). After making a definitive diagnosis of tuberous sclerosis complex (TSC), systemic evaluation was performed. As a result, multiple skin and intracranial lesions characteristic of TSC were identified and we stated administration of everolimus.

Published
2019

130. Total nephroureterocystectomy and urethrectomy due to urothelial carcinoma associated with the BK polyomavirus infection after kidney transplantation: a case report with literature review

Author

MAENOSONO, Ryoichi, OKUMI, Masayoshi, UNAGAMI, Kohei, FUKUDA, Hironori, YOSHIDA, Kazuhiko, KAKUTA, Yoichi, TAKAGI, Toshio, IIZUKA, Junpei, SHIMIZU, Tomokazu, AZUMA, Haruhito, NAGASHIMA, Yoji, TANABE, Kazunari, NITTA, Kosaku, ISHIDA, Hideki, MAENOSONO, Ryoichi, OKUMI, Masayoshi, UNAGAMI, Kohei, FUKUDA, Hironori, YOSHIDA, Kazuhiko, KAKUTA, Yoichi, TAKAGI, Toshio, IIZUKA, Junpei, SHIMIZU, Tomokazu, AZUMA, Haruhito, NAGASHIMA, Yoji, TANABE, Kazunari, NITTA, Kosaku, and ISHIDA, Hideki

Published
2021

135. The Impact of Concomitant Ulcerative Colitis on the Clinical Course in Patients with Primary Sclerosing Cholangitis: An Investigation Using a Nationwide Database in Japan

Author

Moroi, Rintaro, Yano, Kota, Tarasawa, Kunio, Shimoyama, Yusuke, Naito, Takeo, Shiga, Hisashi, Hamada, Shin, Kakuta, Yoichi, Fushimi, Kiyohide, Fujimori, Kenji, Kinouchi, Yoshitaka, and Masamune, Atsushi

Abstract

Introoduction:Primary sclerosing cholangitis (PSC) is a rare disease, especially in Asian countries. PSC often develops during ulcerative colitis (UC). Little is known about the severity of PSC in patients with UC. Thus, this study aimed to investigate the impact of concomitant UC on the clinical course of patients with PSC using a nationwide database in Japan. Methods:We collected data on patients who were admitted for PSC using a nationwide database and divided eligible admissions according to concomitant UC (PSC-UC group vs. PSC-alone group). We conducted propensity score matching and compared the rates of liver transplantation, biliary drainage, and other clinical events between the two groups. We also conducted a multivariate analysis to identify the clinical factors that affect biliary drainage, cholangiocarcinoma, and liver transplantation. Results:We enrolled 672 patients after propensity score matching. The rate of liver transplantation in the PSC-UC group was lower than that in the PSC-alone group (2.2 vs. 5.4%, p= 0.002), whereas the rate of biliary drainage did not differ between the two groups (38.1 vs. 33.8%, p= 0.10). On multivariate analysis, concomitant UC was identified as a clinical factor that decreased the risk of liver transplantation (odds ratio = 0.40, 95% confidence interval: 0.23–0.68, p= 0.0007). Discussion:Concomitant UC in patients with PSC may decrease the risk of liver transplantation. The milder disease activity of PSC with UC is more likely compared to that of PSC without UC.

Published
2023
Full Text
View/download PDF

140. Comprehensive Analysis of microRNA Profiles in Organoids Derived from Human Colorectal Adenoma and Cancer

Author

Nagai, Hiroshi, primary, Kuroha, Masatake, additional, Handa, Tomoyuki, additional, Karasawa, Hideaki, additional, Ohnuma, Shinobu, additional, Naito, Takeo, additional, Moroi, Rintaro, additional, Kanazawa, Yoshitake, additional, Shiga, Hisashi, additional, Hamada, Shin, additional, Kakuta, Yoichi, additional, Naitoh, Takeshi, additional, Kinouchi, Yoshitaka, additional, Shimosegawa, Tooru, additional, and Masamune, Atsushi, additional

Published
2021
Full Text
View/download PDF

141. Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long‐term multicenter cohort study

Author

Imamura, Ryoichi, primary, Nakazawa, Shigeaki, additional, Yamanaka, Kazuaki, additional, Kakuta, Yoichi, additional, Tsutahara, Koichi, additional, Taniguchi, Ayumu, additional, Kawamura, Masataka, additional, Kato, Taigo, additional, Abe, Toyofumi, additional, Uemura, Motohide, additional, Takao, Tetsuya, additional, Kishikawa, Hidefumi, additional, and Nonomura, Norio, additional

Published
2020
Full Text
View/download PDF

142. Influence of a low-dose tacrolimus protocol on the appearance of de novo donor-specific antibodies during 7 years of follow-up after renal transplantation

Author

Unagami, Kohei, primary, Ishida, Hideki, additional, Furusawa, Miyuki, additional, Kitajima, Kumiko, additional, Hirai, Toshihito, additional, Kakuta, Yoichi, additional, Toki, Daisuke, additional, Shimizu, Tomokazu, additional, Omoto, Kazuya, additional, Okumi, Masayoshi, additional, Nitta, Kosaku, additional, and Tanabe, Kazunari, additional

Published
2020
Full Text
View/download PDF

150. Efficacy of urgent colonoscopy for colonic diverticular bleeding: A propensity score‐matched analysis using a nationwide database in Japan

Author

Moroi, Rintaro, primary, Tarasawa, Kunio, additional, Shiga, Hisashi, additional, Yano, Kota, additional, Shimoyama, Yusuke, additional, Kuroha, Masatake, additional, Kakuta, Yoichi, additional, Fushimi, Kiyohide, additional, Fujimori, Kenji, additional, Kinouchi, Yoshitaka, additional, and Masamune, Atsushi, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results